NEW YORK, March. 6, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offeringreports on FOLD, AMPE, APHB, and ARMO which can be accessed for free by signing up to www.wallstequities.com/registration. According to a Reuters' article, the recent volatility in the global stock market may make some investors feel queasy, but
On Monday, shares in Cranbury, New Jersey headquartered Amicus Therapeutics Inc. recorded a trading volume of 4.96 million shares, which was above their three months average volume of 3.07 million shares. The stock ended the session 3.03% lower at $13.77. The Company's shares have gained 76.77% over the past year. The stock is trading 4.66% above its 200-day moving average. Moreover, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have a Relative Strength Index (RSI) of 38.05.
On February 28th, 2018, Amicus Therapeutics announced its results for the year ended December 31st, 2017. Total revenue for the full year 2017 was $36.9 million; total operating expenses were $472.7 million; and operating expenses, as adjusted, excluding the impact of non-cash charges related to the ESSENCE study, were $261.9 million. Net cash spend for the year was $216.5 million, and net loss was $284.0 million. Cash, cash equivalents, and marketable securities totaled $358.6 million at December 31st, 2017. Get the full research report on FOLD for free by clicking below at:
Englewood, Colorado headquartered Ampio Pharmaceuticals Inc.'s stock closed the day 3.48% higher at $2.38 with a total trading volume of 1.25 million shares. The Company's shares have surged 75.00% in the previous three months and 166.88% over the past year. The stock is trading 74.75% above its 200-day moving average. Additionally, shares of Ampio Pharma, which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the US, have an RSI of 41.15. Free research on AMPE can be accessed at:
Shares in San Diego, California headquartered AmpliPhi Biosciences Corp. recorded a trading volume of 240,833 shares. The stock ended yesterday's trading session 2.86% lower at $1.36. The Company's shares have advanced 18.26% in the past month and 30.77% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 14.46% and 35.32%, respectively. Furthermore, shares of AmpliPhi Biosciences, which focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology, have an RSI of 57.79. Visit WallStEquities.com now and sign up for the free research on APHB at:
US-based ARMO BioSciences Inc.'s stock finished Monday's session 8.71% higher at $50.31 with a total trading volume of 204,901 shares. The stock has advanced 67.20% in the last month. Shares of the Company, which focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation, are trading above its 50-day moving average by 22.54%.
On February 20th, 2018, research firm Jefferies initiated a 'Buy' rating on the Company's stock, with a target price of $61 per share. The free technical report on ARMO is available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----amicus-therapeutics-ampio-pharmaceuticals-ampliphi-biosciences-and-armo-biosciences-300608772.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All